Related Experiment Video
Updated: May 25, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
VEGFA+936C/T and -634G/C polymorphisms and gastric cancer risk: a meta-analysis
Hui Liu1, Shaochuang Wang, Chen Huang
1Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Aim:
To estimate the association of vascular endothelial growth factor A (VEGFA) +936C/T and -634G/C polymorphisms and gastric cancer (GC) risk, a meta-analysis was performed. A total of nine studies were identified with 2,281 GC cases and 2,820 controls. This meta-analysis indicated significant associations between the VEGFA -634G/C polymorphism and GC risk were found for GC versus GG (OR 1.21, 95% CI 1.03-1.42) and GG+CC versus GC (OR 0.78, 95% CI 0.68-0.90) overall, for GC versus GG (OR 1.68, 95% CI 1.19-2.35) and GC+CC versus GG (OR 1.54, 95% CI 1.13-2.10) among Europeans, and for GG+CC versus GC (OR 0.82, 95% CI 0.70-0.96) among Asians. No association were observed between GC risk and the variant genotypes of VEGFA +936C/T in different genetic models. In summary, the results suggest that the VEGFA -634G/C polymorphism may contribute to GC susceptibility.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Metabolism: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
